at2221
Glycogen Storage Disease II
Amicus TherapeuticsUNKNOWNPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Glycogen Storage Disease II cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avalglucosidase Alfa Genzyme, a Sanofi Company | Phase 4 | A |
Alglucosidase Alfa Erasmus Medical Center | Phase 4 | A |
Albuterol National Taiwan University Hospital | Phase 4 | BBB |
Rituximab University of Florida | Phase 4 | BB |
METHOTREXATE National Taiwan University Hospital | Phase 4 | BB |
View all 26 →
Same molecule, other indications
at2221 is also rated in:
glycogen storage disease due to acid maltase deficiency, late-onsetDormant
B
Indicative · Phase 3
62 / 100
View asset →glycogen storage disease due to acid maltase deficiency, infantile onsetDormant
D
Indicative · Unknown
30 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →